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Abstract 
 
We report development of a data infrastructure for drug repurposing that takes advantage of two 
currently available chemical ontologies. The data infrastructure includes a database of compound-
target associations augmented with molecular ontological labels. It also contains two 
computational tools for prediction of new associations. We describe two drug-repurposing 
systems: one, Nascent Ontological Information Retrieval for Drug Repurposing (NOIR-DR), 
based on an information retrieval strategy, and another, based on non-negative matrix factorization 
together with compound similarity, that was inspired by recommender systems. We report the 
performance of both tools on a drug-repurposing task.   
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Introduction 
 
Drug repurposing is an efficient strategy for drug discovery, where new targets or activities are 
found for known drugs [1-5]. Drug repurposing requires the efficient representation of existing 
information about the activity of chemical compounds as drugs, and the development of algorithms 
that leverage such information and propose new indications. In this contribution, we develop a 
computational infrastructure for drug repurposing. It includes a database of compounds decorated 
with structural ontological labels and methods for prediction of new drug-like activity. The latter 
methods comprise Nascent Ontological Information Retrieval for Drug Repurposing (NOIR-DR), 
and a recommender engine based on non-negative matrix factorization (NMF). In recent years, 
chemometric representation of molecular structure has seen expansion via construction of 
chemical ontologies [6-8]. General ontologies represent human knowledge in a computationally 
accessible form. Chemical ontologies are motivated by diverse classification goals, such as 
structural relations between molecules, bioactivity of compounds, or even classification of 
cheminformatic descriptors and algorithms.  
 
The primary uses of the existing chemical ontologies are classification of database content, fast 
search and data retrieval, entity resolution, and automated annotation of novel chemicals [7, 8]. 
We recognize that chemical ontological labels fall into the category of structural keys, that is, data 
structures such as bitmaps, in which each entry represents the presence or absence of a specific 
structural feature [9-15]. Work in chemical informatics and machine learning suggests that indeed 
structural keys or molecular fingerprints can be used for predictive analytics of molecular 
properties/activities [16-21]. In this work, we want to benchmark performance of chemical 
ontologies in such predictive tasks.  
 
We have developed a data infrastructure and methods that facilitate drug repurposing via: (a) 
construction of a database of compound-target associations derived from ChEMBL data [22, 23] 
augmented with ontological labels derived from ClassyFire [7] and OntoChem [8] chemical 
ontologies, (b) a database search strategy NOIR-DR, and (c) a recommender system for drug 
repurposing based on NMF. This work consists of forward form of drug repurposing, where 
predictions are made about new targets for the specified compound, and its inverse form, where 
predictions are made about new active compounds for the specified target. Molecular ontological 
labels are human-interpretable and suitable for building search queries by chemists without 
expertise in statistical data analysis. NOIR-DR search takes advantage of this distinctive feature 
of chemical ontologies. Given a target, NOIR-DR strategy is used to retrieve new compounds that 
are expected to exhibit activity toward the target in question, thus solving the inverse drug-
repurposing problem. The recommender system is capable of solving both versions of drug 
repurposing; here we give details about its application to the forward problem. 
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Data and Methods 
 
Ontological labels 
Two programs were used to generate the chemical ontology as the source of features for 
subsequent information retrieval and collaborative filtering steps. One program, which we will call 
OC, was developed by OntoChem [7], and the second program ClassyFire (or CF, for short) was 
developed at the University of Alberta [8].  Both programs take in a SMILES string as input and 
output a list of molecular attributes (chemical labels); see Figure 1. 
 
Figure 1. Example of ClassyFire and OntoChem ontological labels generated for fluocinonide 
molecule. 
 
 
Database augmentation 
 
ChEMBL release 22 was used [22]. This database, of roughly 1.4 million compounds together 
with their known biological activity, has been manually curated for many years. ChEMBL 
associates small molecules with targets, storing also the corresponding bioactivity value. The 
ChEMBL database was augmented using the OC and CF programs to generate ontologies for each 
molecule in the database (Figure 2). We refer to the final form of the database as the ChEMBL 
ontology dB. 
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Figure 2. Construction of the ChEMBL ontology dB. 
 
The two ontology programs (CF and OC) ingest a SMILES string, which is a machine-readable 
representation of the structure of a molecule, and find various attributes of the molecule. For 
example, the molecule is identified as a steroid, an olefin, a carboxylic acid. etc. Other attempts 
have been made to do similar analyses using chemical fingerprints. This has recently been referred 
to as a “similarity ensemble approach” (SEA). Information regarding SEA analysis can be found 
in [17]. 
 
Once the chemical labels have been generated, the ontological attributes are loaded into what 
becomes the enhanced version of the ChEMBL database that now includes the ChEMBL 
molecules, their molecular attributes (chemical ontological labels), the targets associated with 
those molecules, and assay information for the compound-target relationship.  
 
Having decorated the ChEMBL data with chemical ontological labels, the associations between 
compounds and biochemical targets are predicted. The following section describes two drug-
repurposing strategies, one inspired by information retrieval methods, and another inspired by 
recommendation systems. 
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Nascent Ontological Information Retrieval for Drug Repurposing (NOIR-DR) 
 
Among existing definitions of structural keys, fingerprints, and other means of expression of 
molecular structure in a chemometric context, chemical ontologies stand out because they are 
naturally interpretable by subject matter experts. Ontological labels can be used to query chemical 
databases via natural language, which is the preferred form of interaction with the data for non-
experts in cheminformatics and machine learning. Also, ontological labels can be trivially plugged 
into the standard workflows of feature engineering and supervised/unsupervised learning in 
chemometrics. 
 
The first form of drug repurposing we describe is an information retrieval approach that takes 
advantage of the ontology-augmented database (Fig. 1). Recently, a method of generating 
scientific hypotheses based on a semantic “bag of words” embedding of the document content was 
proposed [24]. Along with predictions of activity of several kinases in targeting p53 tumor 
suppressor protein, the paper reported the experimental validation of the activity of several 
predicted p53 kinases. In this approach, the following roles are assigned: the set of compounds in 
the ChEMBL ontology dB is a corpus, compounds are documents, and molecular attributes, 
such as ontological labels, are terms in the documents. Biochemical targets are treated as topics of 
the documents. The information retrieval task is to extract the documents that are relevant to the 
specific topic based on keywords associated with the topic. Selection of the keywords for the query 
can be motivated by external considerations, and using a broad range of statistical analytic tools 
that elucidate term-topic associations. For illustrative purposes, a set of ontological labels 
indicative of the desired compound activity is selected on the basis of a simple ad-hoc scoring of 
terms motivated by 𝜒2 statistics of term counts, as follows.  
 
     𝑇𝑒𝑟𝑚𝑆𝑐𝑜𝑟𝑒𝑖 = (𝑂𝑖 − 𝐸𝑖)
2 𝐸𝑖⁄         (1) 
 
       𝐸𝑖 = 𝐶𝑖 × 𝑁𝑟𝑒𝑙𝑒𝑣𝑎𝑛𝑡 𝑁𝑐𝑜𝑟𝑝𝑢𝑠⁄         (1a) 
 
Here: 
 𝑇𝑒𝑟𝑚𝑆𝑐𝑜𝑟𝑒𝑖 is the score of the search term, i.e., ontological label 𝑖; 
 𝑂𝑖 is the observed count of the term in the documents that are known to be relevant to the search; 
and 
 𝐸𝑖 is the expected count of the term based on the occurrence of the term in the entire corpus. 
 
𝐸𝑖 is computed according to Eq. 1a, where: 
 𝐶𝑖 is the count of the term 𝑖 over the entire corpus; 
 𝑁𝑟𝑒𝑙𝑒𝑣𝑎𝑛𝑡 is the count of the documents that are known to be relevant to the search; and 
 𝑁𝑐𝑜𝑟𝑝𝑢𝑠 is the number of documents in the corpus. 
 
The documents are scored according to Equation 2. 
 
𝐷𝑜𝑐𝑆𝑐𝑜𝑟𝑒𝑖 =
1
𝐿𝑖
 ∑ 𝑇𝑒𝑟𝑚𝑆𝑐𝑜𝑟𝑒𝑗
𝑖
𝑗<𝐿𝑖         (2) 
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where 𝐷𝑜𝑐𝑆𝑐𝑜𝑟𝑒𝑖 is the score of the document, i.e., molecule 𝑖, 𝐿𝑖 is the number of terms found in 
the document, and 𝑇𝑒𝑟𝑚𝑆𝑐𝑜𝑟𝑒𝑗
𝑖 is the score of term 𝑗 found in the document 𝑖. 
 
  
Matrix Factorization for Compound-Target Association  
 
Another possibility is to approach the prediction of compound-target associations as an instance 
of a recommendation problem, and use the machinery of collaborative filtering. In collaborative 
filtering, recommendations are predictions of new associations, such as users with preferred 
movies, shoppers with products, etc. made on the basis of the existing associations. In the simplest 
form, this can be done without any information about the similarity of the involved objects.  
 
Matrix factorization (MF) is a class of algorithms that enables collaborative filtering. The 
conceptual premise of MF is the existence of a few latent factors that explain associations. In 
recommendations of movies, for example, a latent factor might be the genre of a movie and the 
user preference for a specific genre. In compound-target associations, one interpretation of the 
latent factors is the mechanism of drug activity, that is, the mode of interaction between 
compounds and targets. 
 
Various matrix factorization approaches have been explored over the past decade for predicting 
novel drug-target interactions (DTI). Gonen et al [26] presented one of the first works utilizing 
matrix factorization for DTI prediction, using a Bayesian formulation combining dimensionality 
reduction, matrix factorization and binary classification. Cobanoglu et al [27] used Active 
Learning along with Probabilistic Matrix Factorization to predict novel drug-target interactions. 
Zheng et al [28] incorporated multiple drug-drug and target-target similarity measures with an 
Alternating Least Squares algorithm for matrix factorization to predict DTI. Liu et al. [29] 
formulated a Logistic Matrix Factorization model regularized by neighborhood information of 
drugs and targets. Ezzat et al. [30] proposed a Graph Regularized Matrix Factorization approach 
which also makes use of drug-drug and target-target similarity information to improve the 
accuracy. 
 
In its simplest form, MF does not involve any evaluation of the structural similarity of the objects. 
The algorithm can be enhanced along these lines with the hope of improving the prediction quality. 
Incorporation of compound features and similarity metrics into MF algorithms also offers a 
solution to the cold-start problem encountered when a recommendation has to be offered for a 
compound that has no association data available in the dataset. 
 
In this study, we consider two forms of Nonnegative Matrix Factorization (NMF): the basic one, 
without evaluation of pairwise similarity of compounds, and an enhanced one, where similarity 
evaluation for pairs of compounds contributes to the prediction of the compound-target 
associations. NMF is a family of MF algorithms which is suitable for sparse matrices with non-
negative values. NMF algorithms factorize the data matrix X to latent feature matrices U and V, 
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with the constraint that U and V have no negative values. This non-negativity property of NMF 
algorithms allows them to be interpretable and suitable for clustering. 
 
NMF learns 𝑈 and 𝑉 that together minimize the following objective function: 
 
𝐽 =
1
2
‖𝑋 − 𝑈𝑉𝑇‖2,  subject to  𝑈 ≥ 0, 𝑉 ≥ 0      (3) 
 
A multiplicative update rule that can be used to minimize this objective function was proposed in 
[31]. 
 
When learning a model for predicting drug-target interactions, the basic NMF algorithm takes only 
the known interactions into account. Following the intuition that structurally similar compounds 
might be active against the same target, we can incorporate compound similarity information with 
NMF to enable a better model and improve recommendation accuracy. A second MF approach, 
based on [25], uses compound similarity information to force the latent feature representation of 
similar compounds to be closer to each other (compound similarity NMF or CS-NMF). 
 
Suppose we are given a pairwise compound similarity matrix 𝑆, where 𝑆𝑖𝑗 is the similarity or the 
thresholded similarity between compounds i and j. CS-NMF learns 𝑈 and 𝑉 that minimizes the 
following objective function: 
 
 
𝐽 =
1
2
‖𝑋 − 𝑈𝑉𝑇‖2 +
𝜆
2
∑ 𝑆𝑖𝑗‖𝑢𝑖 − 𝑢𝑗‖
2
𝑖,𝑗 , subject to  𝑈 ≥ 0, 𝑉 ≥ 0   (4) 
 
 
Refer to [25] for the detailed solution of this objective function. 
 
The structural similarity between compounds can be calculated using different ways based on the 
representation of compound and similarity metrics used. Here we use the Morgan fingerprint and 
the two ontological fingerprints Ontochem and ClassyFire to represent the compounds. 
Similarity between compounds is measured using Jaccard Similarity. 
 
Results and Discussion 
 
NOIR-DR 
 
As an example, a search query and information retrieval scheme is constructed for the target 
CHEMBL1907611 “Tumour suppressor p53/oncoprotein Mdm2”, or MDM2 for short. This target 
is an oncogene important for the treatment of cancer. The ChEMBL ontology dB database is 
queried for all known compounds with biological activity for this target. ChEMBL22, the version 
of the ChEMBL database used in this study, had a total of 1.4 million molecules of which 585 
molecules had known activity for MDM2.  
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The first task of NOIR-DR is to identify a reference set of ontological labels that can be used for 
the construction of human-interpretable queries for the retrieval of compounds with possible 
activity toward MDM2 from our database. The relevant class of 585 active compounds is narrowed 
down by introducing an activity threshold so that a subset of compounds is selected whose 
effective concentration of biological activity (EC50) is less than 30 nM. Other structure-activity 
relationships, such as lethal dose (LD50), could have been selected for toxicological activity. In 
addition to the activity threshold, construction of the reference set of ontological labels involves 
selection of two more parameters. One is the level of noise, which is the highest allowed count for 
a label over the entire corpus.  Labels are discarded whose observed corpus count exceeds 200K. 
Another parameter is the size of the reference set, in this example limited to 20 labels.   
 
The number of labels that appear more than once among 44 high-activity compounds and do not 
exceed the selected level of noise is 130 for ClassyFire and 122 for OntoChem. For each ontology, 
the top-20 ranking labels are selected according to their computed score (Eq. 1) and two reference 
label sets are constructed. The members of these label sets with their respective scores are shown 
in Table 1. 
 
Among compounds with known activity against MDM2 that do not pass activity threshold, at least 
one of the reference labels from ClassyFire ontology is present in 393 compounds, and at least one 
of the reference labels from OntoChem ontology is present in 314 compounds. Overall, 242 of the 
known active compounds that do not pass the activity threshold carry at least one ClassyFire and 
at least one OntoChem reference label. A consensus between the reference label sets derived from 
the two ontologies is, therefore, achieved on 41% of compounds in question. 
 
In the information retrieval step, the entire corpus of ChEMBL ontology dB compounds minus 
44 high-activity compounds is searched against the query containing the ontological labels from 
the reference set. The compound score is computed according to Eq. 2. Top 100 scoring 
compounds per each ontology are selected. At this point, retrieved data include some of the 
compounds that are known as active against MDM2 per ChEMBL version used in the study, along 
with compounds that are not known to be active against MDM2 per used version of ChEMBL.   
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Table 1. Ontological labels per ClassyFire and OntoChem ontologies that form the reference label 
set and are used to construct search queries for retrieval of compounds relevant to activity against 
MDM2 target. 
 
Label, ClassyFire Score Label, OntoChem Score 
1-phenyltetrahydroisoquinolines 15277 imidazo[1,2-b]thiazoles 2946 
Imidazothiazoles 8505 hydroisoquinoline derivatives 1073 
Isoquinolones and derivatives 1151 tetrahydroisoquinolines 1073 
Stilbenes 1151 36-membered macrocycles 834 
Thiazolines 1062 isoquinolines 666 
Imidazolines 559 lactams 377 
Isothioureas 559 isothioureas 374 
Tetrahydroisoquinolines 553 cyclohexylamines 352 
Thiazolecarboxylic acids and derivatives 544 5,5-membered heterocycles 243 
Isoquinolines and derivatives 506 methylamines 86 
Delta lactams 373 3-aminopyridines 76 
Cyclohexylamines 354 cyclic amides 57 
Piperidinones 301 lactams 57 
Enamines 266 alpha-amino acid derivatives 51 
Chlorobenzenes 247 amino acid derivatives 51 
Pyrrolidinecarboxamides 183 31-40-membered macrocycles 51 
N-methylpiperazines 161 alkylamines 48 
Phenylpiperidines 148 threonine derivatives 42 
Pyrrolidine carboxylic acids and derivatives 145 tertiary mixed amines 42 
Azolines 140 serine derivatives 31 
 
 
These two retrieved sets have 57 molecules in common, constituting a consensus set. Out of 57 
consensus compounds, 9 are known to be active toward MDM2 but did not pass selection 
thresholds and hence were not included into the training set. The remaining 48 consensus 
compounds proceed to validation of their activity from external sources. A viable strategy here is 
a retrospective study [24]1. Out of 48 consensus compounds in question, 15 (Fig. 3) have confirmed 
activity toward human MDM2 according to ChEMBL release 23.  
 
                                                 
1 Our “ChEMBL ontology dB” incorporates compound-target associations according to release 
22 of ChEMBL database [22]. Currently, release 23 of ChEMBL is available [23]; we expect it 
to contain information about compound-target associations that either were discovered between 
ChEMBL releases or took some time to propagate into the database from the literature. 
10 
Figure 3. Consensus compounds whose predicted activity toward MDM2 is confirmed in the 
retrospective study. All these compounds can be tracked down to US patent US 2009/0312310 A1. 
 
 
 
NMF and CS-NMF 
 
In the experiments described in this section a subset of ChEMBL22 is used for training and cross-
validation of NMF and CS-NMF. Compound-target interactions were considered only for the 
targets associated with Homo Sapiens. Only compounds and targets with at least one activity 
reported in the database were selected. The dataset obtained in this manner included 669037 
compounds associated with 3381 targets. Though a primary goal is a reliable prediction of the 
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interactions with IC50 less than 10,000 nM, we retained interactions with higher IC50 values in 
the dataset. The IC50 values are represented in the compound-target adjacency matrix as follows: 
 
- Interactions with IC50 greater than 10,000 nM are represented in data matrix by 1 
- IC50 values 0 to 10,000 nM are linearly transformed to [10, 5], by (20,000 – IC50) / 2000. 
This linear transformation assures that smaller IC50 values are represented by higher 
values in the matrix. 
 
We evaluated the algorithm in 5-fold cross validation with the following performance metrics: 
- RMSE: Root Mean Square Error on test data 
- Recall-at-k: Recall-at-k is the recall on top k predictions and measured as: 
o Take 10,000 compounds at random from test data which have at least 3 targets in 
the training data and 3 targets in the test data 
o For each compound, predict score for all targets 
o Rank targets based on predicted score and take top k targets 
o Measure recall on top k targets 
o Measure mean and standard deviation of recall on the 10,000 test compounds 
 
Results for these performance metrics are shown in Table 2 and Figure 3. Performance of CS-
NMF improves in comparison to NMF in terms of both RMSE and Recall (Table 2). The Rank – 
Recall plot shows the fraction of known test targets. In Figure 3, around 85% of the test targets are 
present in the top 50 target predictions and more than 90% are present in the top 100 target 
predictions. 
 
This result indicates that the information about structural similarity of compounds helps to provide 
better recommendations regarding drug-target interaction. The modest degree of improvement 
suggests a need for deeper investigation of CS-NMF algorithms in the selection of the objective 
function and regularization technique with the goal of increasing the performance gain. 
 
 
Table 2. Performance metrics for NMF and CS-NMF. 
 NMF 
CS-NMF  
(Morgan Fingerprint) 
CS-NMF 
(OntoChem) 
CS-NMF 
(ClassyFire) 
RMSE 3.95 3.93 3.93 3.93 
Recall at 30 0.75 (0.31) 0.76 (0.31) 0.76 (0.31) 0.76 (0.31) 
Recall at 50 0.84 (0.27)  0.85 (0.26) 0.85 (0.26) 0.85 (0.26) 
 
 
The performance metrics also indicate that CS-NMF performs equally well irrespective of the type 
of fingerprints used. The average Root Mean Squared Error (RMSE) and Recall on test data were 
the same when the compound similarity information from Morgan fingerprint, OntoChem and 
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ClassyFire were used. This result indicates that the current version of the NMF algorithm is 
relatively robust with respect to the introduction of feature-based similarity into the optimization 
process. Further development is warranted of specialized NMF algorithms that take full advantage 
of the availability of structural features. 
 
 
 
 
                    Figure 3. Rank – Recall plot for the top 30, 50 and 100 target predictions 
 
Finally, a comparison is provided of the Recommender system for drug repurposing, using NMF 
and CS-NMF with three types of fingerprints and available predicted associations from ChEMBL. 
Predictions are made for a sample of 10 existing drugs available on market. The reported numbers 
are counts of true positive predictions in top-30 predicted targets. 
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Table 3. The number of true positive predictions from our repurposing methodologies and other 
available sources of predictions (columns). Top 30 predictions are considered for 10 sample 
drugs (rows). 
 
 NMF  
CS-NMF 
Morgan  
CS-NMF 
OntoChem 
CS-NMF 
ClassyFire 
ChEMBL 
ALPELISIB BYL719  
PI3K inhibitor 
7 7 7 7 23 
AMITRIPTYLINE 
[CHEMBL629] 
27 27 27 27 173 
DAPAGLIFLOZIN 
[CHEMBL429910] 
2 0 0 0 8 
BEPRIDIL  
[CHEMBL1008] 
13 18 18 18 51 
SITAGLIPTIN 
[CHEMBL1422] 
6 4 4 4 15 
SUMATRIPTAN 
[CHEMBL128] 
21 23 23 23 129 
METHFORMIN 
[CHEMBL1431] 
11 12 12 12 129 
GLIPIZIDE  
[CHEMBL1073] 
13 16 16 16 124 
VALSARTAN 
[CHEMBL1069] 
18 12 12 12 113 
ROPINIROLE  
[CHEMBL589] 
10 15 15 15 30 
Total  128 134 134 134 795 
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Conclusion 
 
An infrastructure for data-driven drug repurposing has been developed that includes a compound-
target association database augmented with ontological labels for compounds. It facilitates two 
approaches to the prediction of new associations, an information retrieval NOIR-DR and an NMF-
based recommender system. 
In information retrieval, human interpretability of ontological labels allows a user without 
expertise in cheminformatics to organize a retrieval process and to arrive at valuable predictions. 
The example described here captures a real use-case of the query construction and a database 
search where the chemist user is able to identify 48 new compounds as potentially active against 
MDM2, to and confirm activity of 15 of them via retrospective methodology. This example is 
extremely encouraging, because it bridges the gap between the data-analytic/machine learning 
community and chemists as subject matter experts. The factor of human interpretability of 
chemical ontological labels is indispensable in enabling human-driven information retrieval. A 
supervised learning version of NOIR-DR, such as a binary classification of compounds in an 
ontological vector space model can be implemented following the methodology of the Knowledge 
Integration Toolkit [24], for example. It is worth noting that two available ontologies, ClassyFire 
and OntoChem, showed a modest degree of consensus in labeling reference data and retrieving 
new data. This is hardly surprising, given that neither ontology is specifically designed to be 
reflective of the chemical knowledge in the specific domain of anti-cancer drug activity. 
Development of domain-specific semantic assets, such as ontologies, would be desirable to 
improve information retrieval performance. 
In addressing the applicability of chemical ontologies for drug repurposing via machine learning, 
(such as the NMF-based recommender system), two forms of NMF are benchmarked, with and 
without compound similarity evaluation. Introduction of structural features both in the form of 
Morgan structural fingerprints and ontological labels led to the improvement of NMF performance 
metrics. Differences in performance were not observed between the effect of structural fingerprints 
and ontological labels nor between performance of either of the two types of ontological labels. 
The full potential of CS-NMF in combination with ontological labels will be realized on 
development of specialized objective functions and regularization techniques along with problem-
specific ontologies. 
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